Lobeglitazone (BioDeep_00001871483)
代谢物信息卡片
Lobeglitazone
化学式: C24H24N4O5S (480.1467334)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC(=NC=N3)OC4=CC=C(C=C4)OC
InChI: InChI=1S/C24H24N4O5S/c1-28(21-14-22(26-15-25-21)33-19-9-7-17(31-2)8-10-19)11-12-32-18-5-3-16(4-6-18)13-20-23(29)27-24(30)34-20/h3-10,14-15,20H,11-13H2,1-2H3,(H,27,29,30)
描述信息
A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BG - Thiazolidinediones
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98241 - Thiazolidinedione Antidiabetic Agent
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- ChEBI: CHEBI:136052
- PubChem: 9826451
- DrugBank: DB09198
- ChEMBL: CHEMBL3585580
- CAS: 607723-33-1
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Shashank R Joshi, Saibal Das, Suja Xaviar, Shambo Samrat Samajdar, Indranil Saha, Sougata Sarkar, Shatavisa Mukherjee, Santanu Kumar Tripathi, Jyotirmoy Pal, Nandini Chatterjee. Efficacy and safety of lobeglitazone, a new Thiazolidinedione, as compared to the standard of care in type 2 diabetes mellitus: A systematic review and meta-analysis.
Diabetes & metabolic syndrome.
2023 Jan; 17(1):102703. doi:
10.1016/j.dsx.2022.102703. [PMID: 36634469] - Soree Ryang, Sang Soo Kim, Ji Cheol Bae, Ji Min Han, Su Kyoung Kwon, Young Il Kim, Il Seong Nam-Goong, Eun Sook Kim, Mi-Kyung Kim, Chang Won Lee, Soyeon Yoo, Gwanpyo Koh, Min Jeong Kwon, Jeong Hyun Park, In Joo Kim. A double-blind, Randomized controlled trial on glucose-lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase-4 inhibitor therapy: REFIND study.
Diabetes, obesity & metabolism.
2022 09; 24(9):1800-1809. doi:
10.1111/dom.14766. [PMID: 35581902] - Da Hea Seo, Young Ju Suh, Yongin Cho, Seong Hee Ahn, Seongha Seo, Seongbin Hong, Yong-Ho Lee, Young Ju Choi, Eunjig Lee, So Hun Kim. Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice.
Yonsei medical journal.
2022 Sep; 63(9):825-833. doi:
10.3349/ymj.2022.63.9.825. [PMID: 36031782] - Jungsin Park, Choon Ok Kim, Eun Sil Oh, Jung Il Lee, Ja Kyung Kim, Sang Hoon Ahn, Do Young Kim, Seung Up Kim, Beom Kyung Kim, Yong Eun Chung, Se-Mi Kim, Min Soo Park. Effects of Hepatic Impairment on the Pharmacokinetic Profile and Safety of Lobeglitazone.
Clinical pharmacology in drug development.
2022 05; 11(5):576-584. doi:
10.1002/cpdd.1045. [PMID: 35255191] - Selikem Nuwormegbe, Na-Young Park, Sun Woong Kim. Lobeglitazone attenuates fibrosis in corneal fibroblasts by interrupting TGF-beta-mediated Smad signaling.
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie.
2022 Jan; 260(1):149-162. doi:
10.1007/s00417-021-05370-2. [PMID: 34468828] - Yu Kyong Kim, Jun Gi Hwang, Min Kyu Park. No Relevant Pharmacokinetic Drug-Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects.
Drug design, development and therapy.
2021; 15(?):1725-1734. doi:
10.2147/dddt.s302215. [PMID: 33953542] - Sin Gon Kim, Kyoung Jin Kim, Kun Ho Yoon, Sung Wan Chun, Kyong Soo Park, Kyung Mook Choi, Soo Lim, Ji-Oh Mok, Hyoung Woo Lee, Ji A Seo, Bong-Soo Cha, Mi Kyung Kim, Ho Sang Shon, Dong Seop Choi, Doo Man Kim. Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks.
Diabetes, obesity & metabolism.
2020 10; 22(10):1869-1873. doi:
10.1111/dom.14085. [PMID: 32406573] - Yu Yang, Yu Zhao, Wenzhen Li, Yuyao Wu, Xin Wang, Yijie Wang, Tingmei Liu, Tinghong Ye, Yongmei Xie, Zhiqiang Cheng, Jun He, Peng Bai, Yiwen Zhang, Liang Ouyang. Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment.
European journal of medicinal chemistry.
2020 Jul; 197(?):112311. doi:
10.1016/j.ejmech.2020.112311. [PMID: 32339855] - Seol Ju Moon, Kyung-Sang Yu, Min-Gul Kim. An Assessment of Pharmacokinetic Interaction Between Lobeglitazone and Sitagliptin After Multiple Oral Administrations in Healthy Men.
Clinical therapeutics.
2020 06; 42(6):1047-1057. doi:
10.1016/j.clinthera.2020.04.005. [PMID: 32362346] - Sangwoo Park, Jae Won Ahn, YoungJu Jo, Ha-Young Kang, Hyun Jung Kim, Yeongmi Cheon, Jin Won Kim, YongKeun Park, Seongsoo Lee, Kyeongsoon Park. Label-Free Tomographic Imaging of Lipid Droplets in Foam Cells for Machine-Learning-Assisted Therapeutic Evaluation of Targeted Nanodrugs.
ACS nano.
2020 02; 14(2):1856-1865. doi:
10.1021/acsnano.9b07993. [PMID: 31909985] - Kyungho Jang, Ji-Young Jeon, Seol Ju Moon, Min-Gul Kim. Evaluation of the Pharmacokinetic Interaction Between Lobeglitazone and Dapagliflozin at Steady State.
Clinical therapeutics.
2020 02; 42(2):295-304. doi:
10.1016/j.clinthera.2020.01.003. [PMID: 31992459] - Sun-Young Kim, Ji-Young Jeon, Shin Jung Park, Min-Gul Kim. Pharmacokinetics of a Lobeglitazone/Metformin Fixed-Dose Combination Tablet (CKD-395 0.5/1000 mg) Versus Concomitant Administration of Single Agents and the Effect of Food on the Metabolism of CKD-395 in Healthy Male Subjects.
Clinical pharmacology in drug development.
2019 07; 8(5):576-584. doi:
10.1002/cpdd.625. [PMID: 30329224] - So Jin Lee, Min-Gul Kim, Shin-Jung Park, Ji-Young Jeon. Pharmacokinetics and bioequivalence of 0.5 mg lobeglitazone tablets in healthy male subjects
.
International journal of clinical pharmacology and therapeutics.
2018 Sep; 56(9):426-433. doi:
10.5414/cp203134. [PMID: 29932413] - Jah Yeon Choi, Jiheun Ryu, Hyun Jung Kim, Joon Woo Song, Joo Hee Jeon, Dae-Hee Lee, Dong Joo Oh, Dae-Gab Gweon, Wang-Yuhl Oh, Hongki Yoo, Kyeongsoon Park, Jin Won Kim. Therapeutic Effects of Targeted PPARɣ Activation on Inflamed High-Risk Plaques Assessed by Serial Optical Imaging In Vivo.
Theranostics.
2018; 8(1):45-60. doi:
10.7150/thno.20885. [PMID: 29290792] - Min A Lee, Lingchen Tan, Huiseon Yang, Yeong-Gwan Im, Young Jun Im. Structures of PPARγ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs.
Scientific reports.
2017 12; 7(1):16837. doi:
10.1038/s41598-017-17082-x. [PMID: 29203903] - Chang-Soon Yim, Yoo-Seong Jeong, Song-Yi Lee, Wonji Pyeon, Heon-Min Ryu, Jong-Hwa Lee, Kyeong-Ryoon Lee, Han-Joo Maeng, Suk-Jae Chung. Specific Inhibition of the Distribution of Lobeglitazone to the Liver by Atorvastatin in Rats: Evidence for a Rat Organic Anion Transporting Polypeptide 1B2-Mediated Interaction in Hepatic Transport.
Drug metabolism and disposition: the biological fate of chemicals.
2017 03; 45(3):246-259. doi:
10.1124/dmd.116.074120. [PMID: 28069721] - Yong Ho Lee, Jae Hyeon Kim, So Ra Kim, Heung Yong Jin, Eun Jung Rhee, Young Min Cho, Byung Wan Lee. Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness.
Journal of Korean medical science.
2017 01; 32(1):60-69. doi:
10.3346/jkms.2017.32.1.60. [PMID: 27914133] - Sun Hwa Kim, Sin Gon Kim, Doo Man Kim, Jeong-Taek Woo, Hak Chul Jang, Choon Hee Chung, Kyung Soo Ko, Jeong Hyun Park, Yong Soo Park, Sang Jin Kim, Dong Seop Choi. Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study.
Diabetes research and clinical practice.
2015 Dec; 110(3):e27-30. doi:
10.1016/j.diabres.2015.09.009. [PMID: 26458774] - Jong-Hwa Lee, Chi-Kyoung Noh, Chang-Soon Yim, Yoo-Seong Jeong, Sung Hoon Ahn, Wooin Lee, Dae-Duk Kim, Suk-Jae Chung. Kinetics of the Absorption, Distribution, Metabolism, and Excretion of Lobeglitazone, a Novel Activator of Peroxisome Proliferator-Activated Receptor Gamma in Rats.
Journal of pharmaceutical sciences.
2015 Sep; 104(9):3049-59. doi:
10.1002/jps.24378. [PMID: 25648999] - S-M Jin, C-Y Park, Y M Cho, B J Ku, C W Ahn, B-S Cha, K W Min, Y A Sung, S H Baik, K W Lee, K-H Yoon, M-K Lee, S W Park. Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension.
Diabetes, obesity & metabolism.
2015 Jun; 17(6):599-602. doi:
10.1111/dom.12435. [PMID: 25580775] - Jin Ah Jung, Soo-Yun Lee, Tae-Eun Kim, Jung-Ryul Kim, Chin Kim, Wooseong Huh, Jae-Wook Ko. Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin.
Drug design, development and therapy.
2015; 9(?):737-43. doi:
10.2147/dddt.s76591. [PMID: 25767371] - Min Kyu Park, Tae-Eun Kim, JaeWoo Kim, Chin Kim, Seo Hyun Yoon, Joo-Youn Cho, In-Jin Jang, Kyung-Sang Yu, Kyoung Soo Lim. Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-γ agonist, after a single oral administration in healthy female subjects.
Clinical drug investigation.
2014 Jul; 34(7):467-74. doi:
10.1007/s40261-014-0197-y. [PMID: 24802657] - Sin Gon Kim, Doo Man Kim, Jeong-Taek Woo, Hak Chul Jang, Choon Hee Chung, Kyung Soo Ko, Jeong Hyun Park, Yong Soo Park, Sang Jin Kim, Dong Seop Choi. Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial.
PloS one.
2014; 9(4):e92843. doi:
10.1371/journal.pone.0092843. [PMID: 24736628] - Donghoon Shin, Tae-Eun Kim, Seo Hyun Yoon, Joo-Youn Cho, Sang-Goo Shin, In-Jin Jang, Kyung-Sang Yu. Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects.
Current medical research and opinion.
2012 Jul; 28(7):1213-20. doi:
10.1185/03007995.2012.703131. [PMID: 22697273] - Jung Won Kim, Jung-Ryul Kim, Sojeong Yi, Kwang-Hee Shin, Hyun-Suk Shin, Seo Hyun Yoon, Joo-Youn Cho, Dal-Hyun Kim, Sang-Goo Shin, In-Jin Jang, Kyung-Sang Yu. Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-γ agonist: a single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects.
Clinical therapeutics.
2011 Nov; 33(11):1819-30. doi:
10.1016/j.clinthera.2011.09.023. [PMID: 22047812] - Jong-Hwa Lee, Young-Ah Woo, In-Chang Hwang, Choong-Yong Kim, Dae-Duk Kim, Chang-Koo Shim, Suk-Jae Chung. Quantification of CKD-501, lobeglitazone, in rat plasma using a liquid-chromatography/tandem mass spectrometry method and its applications to pharmacokinetic studies.
Journal of pharmaceutical and biomedical analysis.
2009 Dec; 50(5):872-7. doi:
10.1016/j.jpba.2009.06.003. [PMID: 19577404]